Lymphoid organs’ metabolism and its role in predicting the outcomes of patients with malignant melanoma treated with immunotherapy: an exploratory study
Background This study aimed to evaluate the changes in 2-[18F]-FDG PET/CT parameters of lymphoid organs and their association with clinical outcomes in melanoma patients undergoing immunotherapy. Materials and methods Ninety-two consecutive patients with malignant melanoma were enrolled in the study. Patients underwent serial 2-[18F]-FDG PET/CT scans at baseline (PET0), 6 months (PET1), 18 months (PET2), and 36 months after starting immunotherapy. Visual and semiquantitative analyses were performed by two experienced nuclear medicine specialists. Bone marrow uptake was visually quantified using a scale system ranging from 1 to 5, mean standardized uptake values (SUVmean) of the liver and spleen were measured, and the Spleen Liver Ratio (SLR) was calculated. Clinical assessments and disease outcomes were recorded based on physical examinations, routine blood work, serum chemistry studies, and conventional imaging. Progression-free survival (PFS) and overall survival (OS) were also determined. Results Most patients received anti-PD1 therapy, and radiotherapy was combined with systemic treatment in some cases (n = 12 patients). After 6, and 18 months, clinical disease control was achieved in 74% and 74%, respectively. Patients without clinical disease control exhibited higher bone marrow FDG uptake and an increase in the sites of metabolic lesions. Median SLR values were slightly higher in patients without disease control after 6 and 18 months, but lower after 36 months. At PET0, the median SLR was higher in alive patients than those who died, while it was similar in the following scans. Patients with signs of inflammation on PET1 had a higher baseline SLR, which decreased in the subsequent PET2 scan. Conclusions Changes in bone marrow FDG uptake may serve as potential indicators of treatment response and disease outcomes. SLR would be considered an interesting predictive and prognostic indicator. This study provides insights into the dynamic changes of metabolic parameters during immunotherapy and their clinical implications in malignant melanoma patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Clinical and translational imaging - 12(2024), 2 vom: 13. Feb., Seite 213-223 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Rimini, Maria Luisa [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s40336-023-00614-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055375995 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055375995 | ||
| 003 | DE-627 | ||
| 005 | 20240402064730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240402s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40336-023-00614-z |2 doi | |
| 035 | |a (DE-627)SPR055375995 | ||
| 035 | |a (SPR)s40336-023-00614-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a De Rimini, Maria Luisa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lymphoid organs’ metabolism and its role in predicting the outcomes of patients with malignant melanoma treated with immunotherapy: an exploratory study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background This study aimed to evaluate the changes in 2-[18F]-FDG PET/CT parameters of lymphoid organs and their association with clinical outcomes in melanoma patients undergoing immunotherapy. Materials and methods Ninety-two consecutive patients with malignant melanoma were enrolled in the study. Patients underwent serial 2-[18F]-FDG PET/CT scans at baseline (PET0), 6 months (PET1), 18 months (PET2), and 36 months after starting immunotherapy. Visual and semiquantitative analyses were performed by two experienced nuclear medicine specialists. Bone marrow uptake was visually quantified using a scale system ranging from 1 to 5, mean standardized uptake values (SUVmean) of the liver and spleen were measured, and the Spleen Liver Ratio (SLR) was calculated. Clinical assessments and disease outcomes were recorded based on physical examinations, routine blood work, serum chemistry studies, and conventional imaging. Progression-free survival (PFS) and overall survival (OS) were also determined. Results Most patients received anti-PD1 therapy, and radiotherapy was combined with systemic treatment in some cases (n = 12 patients). After 6, and 18 months, clinical disease control was achieved in 74% and 74%, respectively. Patients without clinical disease control exhibited higher bone marrow FDG uptake and an increase in the sites of metabolic lesions. Median SLR values were slightly higher in patients without disease control after 6 and 18 months, but lower after 36 months. At PET0, the median SLR was higher in alive patients than those who died, while it was similar in the following scans. Patients with signs of inflammation on PET1 had a higher baseline SLR, which decreased in the subsequent PET2 scan. Conclusions Changes in bone marrow FDG uptake may serve as potential indicators of treatment response and disease outcomes. SLR would be considered an interesting predictive and prognostic indicator. This study provides insights into the dynamic changes of metabolic parameters during immunotherapy and their clinical implications in malignant melanoma patients. | ||
| 650 | 4 | |a Immunotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a FDG PET/CT |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lymphoid organs |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Bianchi, Andrea |4 aut | |
| 700 | 1 | |a Annovazzi, Alessio |4 aut | |
| 700 | 1 | |a D’Arienzo, Davide |4 aut | |
| 700 | 1 | |a Valente, Tullio |4 aut | |
| 700 | 1 | |a Sciuto, Rosa |4 aut | |
| 700 | 1 | |a Di Traglia, Silvia |4 aut | |
| 700 | 1 | |a Nappi, Anna Giulia |4 aut | |
| 700 | 1 | |a Ferrari, Cristina |4 aut | |
| 700 | 1 | |a Rubini, Giuseppe |4 aut | |
| 700 | 1 | |a Panareo, Stefano |4 aut | |
| 700 | 1 | |a Urso, Luca |4 aut | |
| 700 | 1 | |a Bartolomei, Mirco |4 aut | |
| 700 | 1 | |a Aricò, Demetrio |4 aut | |
| 700 | 1 | |a Bombaci, Michelangelo |4 aut | |
| 700 | 1 | |a Caponnetto, Domenica |4 aut | |
| 700 | 1 | |a Gusella, Sara |4 aut | |
| 700 | 1 | |a Spimpolo, Alessandro |4 aut | |
| 700 | 1 | |a Carriere, Cinzia |4 aut | |
| 700 | 1 | |a Balma, Michele |4 aut | |
| 700 | 1 | |a Buschiazzo, Ambra |4 aut | |
| 700 | 1 | |a Gallicchio, Rosj |4 aut | |
| 700 | 1 | |a Storto, Giovanni |4 aut | |
| 700 | 1 | |a Filippi, Luca |4 aut | |
| 700 | 1 | |a Evangelista, Laura |0 (orcid)0000-0002-5955-9488 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational imaging |d Springer International Publishing, 2013 |g 12(2024), 2 vom: 13. Feb., Seite 213-223 |w (DE-627)SPR036344834 |w (DE-600)2712000-4 |x 2281-7565 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:2 |g day:13 |g month:02 |g pages:213-223 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40336-023-00614-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 2 |b 13 |c 02 |h 213-223 | ||